Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 1, 2008, Pages 236-247

  Masutani, Satoshi ^a   Cheng, Heng Jie ^a   Hyttilä Hopponen, Minja ^b   Levijoki, Jouko ^b   Heikkilä, Aira ^b   Vuorela, Arja ^b   Little, William C ^a   Cheng, Che Ping ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOSIMENDAN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; EXPERIMENTAL DOG; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART RATE; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; SYSTOLE; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; CARDIOTONIC AGENTS; DIASTOLE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HEMODYNAMICS; HYDRAZONES; MYOCARDIAL CONTRACTION; PYRIDAZINES; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 41149149256     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.134940     Document Type: Article

References (37)

1. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, and Scheinin H (2004) Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 23:213-222.
2. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7:882-887.
3. Bristow MR (2000) [beta]-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569.
4. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, and Little WC (1996) Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 78:880-892.
5. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, and Little WC (2001) The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280:H1853-H1860.
6. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77:107-113.
7. Endoh M (2002) Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40:323-338.
8. 2+ sensitizers rescue patients from chronic congestive heart failure? Br J Pharmacol 150:826-828.
9. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO Study): a randomised double-blind trial. Lancet 360:196-202.
10. Haikala H and Linden IB (1995) Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1):S10-S19.
11. Harjola VP, Peuhkurinen K, Nieminen MS, Niemel M, and Sundberg S (1999) Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 83:I4-I8.
12. Harkin CP, Pagel PS, Tessmer JP, and Warltier DC (1995) Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 26:179-188.
13. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, and Just H (1998) Influence of the novel inotropic agent, levosimendan, on isometric tension and calcium cycling in failing human myocardium. Circulation 98:2141-2147.
14. Hgashiyama A, Watkins MW, Chen Z, and LeWinter MM (1995) Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 92:3094-3104.
15. Hosenpud JD and Group ftOLS (1999) Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 83:I9-I11.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Kaheinen P, Pollesello P, Levijoki J, and Haikala H (2001) Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37:367-374.
18. Kass DA and Solaro RJ (2006) Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113:305-315.
19. Lehtonen L and Poder P (2007) The utility of levosimendan in the treatment of heart failure. Ann Int Med 39:2-17.
20. Lenfant C (1994) Report of the Task Force on Research in Heart Failure. Circulation 90:1118-1123.
21. Little WC and Cheng CP (1994) Coupling of the left ventricular and arterial system. Med Biol Eng Comput 32:205-209.
22. Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kyto V, Finckenberg P, Colucci WS, Levijoki J, Pollesello P, et al. (2007) Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 150:851-861.
23. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422-1432.
24. Morimoto A, Hasegawa H, Cheng HJ, Little WC, and Cheng CP (2004) Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 286:H2425-H2433.
25. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, and Remme WJ (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903-1912.
26. Nozawa T, Cheng CP, Noda T, and Little WC (1994) Effect of exercise on left ventricular mechanical efficiency in conscious dogs. Circulation 90:3047-3054.
27. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, and Warltier DC (1997) Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 29:563-573.
28. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, Iliodromitis E, and Kremastinos D (2004) Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93:1309-1312.
29. Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, and Lehtonen L (2003) Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 41:365-373.
30. Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, and Lehtonen L (2004) Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 44:1143-1150.
31. Suga H and Sagawa K (1979) Graphical estimation of ventricular wall force and stress from pressure-volume diagram. Am J Physiol Heart Circ Physiol 236:H787-H789.
32. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, and Cheng CP (2005) Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 288:H914-H922.
33. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, and Burkhoff D (1996) Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279:120-127.
34. Trikas A, Antoniades C, Latsios G, Vasiliadou K, Karamitros I, Tousoulis D, Tentolouris C, and Stefanadis C (2006) Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 8:804-809.
35. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, and Voipio-Pulkki LM (2000) Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68:522-531.
36. + channel in rat arterial myocytes. Eur J Pharmacol 333:249-259.
37. + channel in rat ventricular cells. J Pharmacol Exp Ther 283:375-383.